BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:IEV407 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of IEV407\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07604571-9114@assetmemo.bio
DTSTAMP:20261121T005833Z
DTSTART;VALUE=DATE:20320608
DTEND;VALUE=DATE:20320609
SUMMARY:IEV407: Phase 1 readout est. (NCT07604571)
DESCRIPTION:IEV407\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStudy: 
 Study of IEV407 as Single Agent or in Combination in Patients With Advance
 d HR+/HER2- Breast Cancer\nEstimated primary completion: 8 June 2032. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/iev407#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07604571
URL:https://assetmemo.bio/drug/iev407#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
